Principles of Anticancer Drug Development
Herausgegeben:Garrett-Mayer, Elizabeth;Mitarbeit:Hidalgo, Manuel; Eckhardt, S. Gail; Clendeninn, Neil J.
Principles of Anticancer Drug Development
Herausgegeben:Garrett-Mayer, Elizabeth;Mitarbeit:Hidalgo, Manuel; Eckhardt, S. Gail; Clendeninn, Neil J.
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.
Andere Kunden interessierten sich auch für
![Macromolecular Anticancer Therapeutics]( "Macromolecular Anticancer Therapeutics")
Macromolecular Anticancer Therapeutics206,99 €![Mechanisms in Carcinogenesis and Cancer Prevention]( "Mechanisms in Carcinogenesis and Cancer Prevention")
Harri U. Vainio / Eino Hietanen (eds.)Mechanisms in Carcinogenesis and Cancer Prevention293,99 €![Anticancer Drug Development Guide]( "Anticancer Drug Development Guide")
TeicherAnticancer Drug Development Guide231,99 €![Novel Anticancer Agents]( "Novel Anticancer Agents")
Alex A. AdjeiNovel Anticancer Agents167,99 €![Medicinal Chemistry of Anticancer Drugs]( "Medicinal Chemistry of Anticancer Drugs")
Carmen AvendañoMedicinal Chemistry of Anticancer Drugs125,99 €![Der Krebspatient in der Apotheke]( "Der Krebspatient in der Apotheke")
Der Krebspatient in der Apotheke48,00 €![Cisplatin]( "Cisplatin")
Bernhard Lippert (Hrsg.)Cisplatin164,99 €-
-
-
A practical guide to the design, conduction, analysis and reporting of clinical trials with anticancer drugs.
Produktdetails
- Produktdetails
- Cancer Drug Discovery and Development
- Verlag: Humana / Springer New York / Springer, Berlin
- Artikelnr. des Verlages: 12750610, 978-1-4419-7357-3
- 2011
- Seitenzahl: 692
- Erscheinungstermin: 30. Dezember 2010
- Englisch
- Abmessung: 241mm x 160mm x 40mm
- Gewicht: 1154g
- ISBN-13: 9781441973573
- ISBN-10: 1441973575
- Artikelnr.: 30686192
- Cancer Drug Discovery and Development
- Verlag: Humana / Springer New York / Springer, Berlin
- Artikelnr. des Verlages: 12750610, 978-1-4419-7357-3
- 2011
- Seitenzahl: 692
- Erscheinungstermin: 30. Dezember 2010
- Englisch
- Abmessung: 241mm x 160mm x 40mm
- Gewicht: 1154g
- ISBN-13: 9781441973573
- ISBN-10: 1441973575
- Artikelnr.: 30686192
Section 1: Chapter 1: Basic Biostatistics for the Clinical Trialist
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou
Section 1: Chapter 1: Basic Biostatistics for the Clinical Trialist
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou
Authors: Elizabeth G. Hill and Elizabeth Garrett-Mayer Chapter 2:
Fundamental Concepts in Clinical Pharmacology Authors: Daniel L. Gustafson
and Erica L. Bradshaw-Pierce Chapter 3: Bioanalytical Methods in Clinical
Drug Development Authors: Walter J. Loos, Peter de Bruijn, Alex Sparreboom
Section 2 Chapter 1: Preclinical Models for Anticancer Drug Development
Author: Edward Sausville Section 3 Chapter 1: Phase I Clinical Trials with
Anticancer Agents Authors: Stephen Leong, Justin Call, Alex Adjei, Wells
Messersmith Chapter 2: Phase II Clinical Trials with Anticancer Agents
Authors: Hui Gan, J. Jack Lee, Lillian L. Siu Chapter 3: Phase III Clinical
Trials with Anticancer Agents Authors: Wendy Parulekar and Daniel J.
Sargent Chapter 4: Pharmacokinetic Studies in Early Anticancer Drug
Development Authors: Sharyn D Baker and Alex Sparreboom Chapter 5:
Pharmacodynamic Studies in Early Phase Drug Development Authors: D. Ross
Camidge, Robert C. Doebele and Antonio Jimeno Chapter 6: Prediction of
Antitumor response Authors: Yu Shyr and Fred R. Hirsch Chapter 7: Imaging
Studies in Anticancer Drug Development Author: David Mankoff Section 4
Chapter 1: Role of the US Food and Drug Administration in Cancer Drug
Development Authors: Ann T. Farrell, Ramzi N. Dagher and Richard Pazdur
Section 5 Chapter 1: Early Clinical Trials with Cytotoxic Agents Authors:
M.J.A. de Jonge and Jaap Verweij Chapter 2: Challenges and Sucesses in
Developing Effective Anti-Angiogenic Agents Authors: Laura QM Chow and S
Gail Eckhardt Chapter 3: Targeted Therapeutics in Cancer Treatment Authors:
Colin D. Weekes and Manuel Hidalgo Chapter 4: Cancer Chemoprevention
Authors: Christopher H. Lieu, William N. William Jr., Scott M. Lippman
Chapter 5: Combined Modality Therapy in Cancer Management Authors: David
Raben and Kyle Rusthoven Chapter 6: Cancer Vaccines Author: Dan Laheru
Chapter 7: Optimizing the Development of Antibodies as Treatment for Cancer
Authors: Craig P Carden, Hendrik-Tobias Arkenau and JS de Bono Chapter 8:
Oligonucleotide Therapeutics Authors: Cy A Stein, Britta Hoehn, John Rossi
Chapter 9: Anticancer Drug Development in Pediatric Patients Authors: Lia
Gore and Margaret Macy Chapter 10: Clinical Trials in Special Populations
Authors: S. Percy Ivy, MD; Merrill J. Egorin, MD; Chris H. Takimoto, MD,
PhD; and Jeannette Y. Wick, RPh Section 6: Chapter 1. NCI Sponsored
Clinical Trials Author: Janet E. Dancey and Andriana Papaconstantinou